Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir Patent Expiration
Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir is Used for: Treatment of HCV infection. It was first introduced by Abbvie Inc
Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir Patents
Given below is the list of patents protecting Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Viekira Pak (copackaged) | US10201542 | Formulations of pyrimidinedione derivative compounds | Oct 18, 2033 | Abbvie |
| Viekira Pak (copackaged) | US9629841 | Formulations of pyrimidinedione derivative compounds | Oct 18, 2033 | Abbvie |
| Viekira Pak (copackaged) | US8466159 | Methods for treating HCV | Sep 04, 2032 | Abbvie |
| Viekira Pak (copackaged) | US8492386 | Methods for treating HCV | Sep 04, 2032 | Abbvie |
| Viekira Pak (copackaged) | US8680106 | Methods for treating HCV | Sep 04, 2032 | Abbvie |
| Viekira Pak (copackaged) | US8685984 | Methods for treating HCV | Sep 04, 2032 | Abbvie |
| Viekira Pak (copackaged) | US8691938 | Anti-viral compounds | Apr 13, 2032 | Abbvie |
| Viekira Pak (copackaged) | US8686026 | Solid compositions | Jun 09, 2031 | Abbvie |
| Viekira Pak (copackaged) | US8420596 | Macrocyclic hepatitis C serine protease inhibitors | Apr 10, 2031 | Abbvie |
| Viekira Pak (copackaged) | US9044480 | Compositions and methods for treating HCV | Apr 10, 2031 | Abbvie |
| Viekira Pak (copackaged) | US9006387 | Anti-viral compounds | Jun 10, 2030 | Abbvie |
| Viekira Pak (copackaged) | US8642538 | Macrocyclic hepatitis C serine protease inhibitors | Sep 10, 2029 | Abbvie |
| Viekira Pak (copackaged) | US8188104 | Anti-infective agents and uses thereof | May 17, 2029 | Abbvie |
| Viekira Pak (copackaged) | US8501238 | Anti-infective agents and uses thereof | Dec 19, 2028 | Abbvie |
| Viekira Pak (copackaged) | US9139536 | Anti-infective agents and uses thereof | Nov 09, 2028 | Abbvie |
| Viekira Pak (copackaged) | US8268349 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Viekira Pak (copackaged) | US8399015 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Viekira Pak (copackaged) | US7364752 | Solid dispersion pharamaceutical formulations |
Nov 10, 2020
(Expired) | Abbvie |
| Viekira Pak (copackaged) | US7148359 | Polymorph of a pharmaceutical |
Jul 19, 2019
(Expired) | Abbvie |
| Viekira Pak (copackaged) | US6037157 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Viekira Pak (copackaged) | US6703403 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir's patents.
Latest Legal Activities on Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir's Patents
Given below is the list recent legal activities going on the following patents of Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Oct, 2023 | US8188104 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Feb, 2023 | US9139536 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9044480 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US9006387 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2022 | US10201542 |
| Patent Term Extension Certificate Critical | 19 Apr, 2022 | US8501238 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Sep, 2021 | US8691938 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Sep, 2021 | US8686026 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Jul, 2021 | US8642538 |
| Notice of Final Determination -Eligible | 16 Feb, 2021 | US8501238 |
Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir's Family Patents
